Delfi Diagnostics
- 18/07/2022
- Series B
- $225,000,000
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
- Industry Biotechnology
- Website https://delfidiagnostics.com/
- LinkedIn https://www.linkedin.com/company/delfi-diagnostics/
Related People
Victor Velculescu, MD, PhDFounder
Dr. Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word “transcriptome" to describe the patterns that could now obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. These efforts have led to new FDA approved therapies and diagnostic tests widely used for cancer patients. More recently, his group has developed non-invasive liquid biopsy approaches for early detection and monitoring of cancer patients. These discoveries provide new paradigms for our understanding of human cancer that have benefited patients worldwide.